Acurx Pharmaceuticals, Inc. (ACXP) stock
ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.99+0.05 (+5.88%)
Close on Nov 17, 2026Market cap $5.22MP/E –Yield –
Acurx Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Acurx Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$7.67M. For fiscal 2025 it was -$8.09M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.09M | – |
| FY2024 | Dec 31, 2024 | -$14.12M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.72M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.12M | – |
See a number that looks wrong?